New diabetes drugs under Real-World watch: 15,000 patients enrolled

NCT ID NCT05926414

Ongoing Disease control Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is observing 15,000 adults with type 2 diabetes who are starting Envlo or Envlomet SR tablets. Researchers will check how well these drugs control blood sugar (HbA1c) over 24 weeks and monitor for side effects. The goal is to see if they work safely in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Enavogliflozin (Envlo tablet or Envlomet SR tablet)

What this could lead to

If successful, this could confirm that Envlo or Envlomet SR helps control blood sugar in type 2 diabetes patients in real-world settings.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for 24 weeks, so long-term effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS (TYPE 2)

Contacts and locations

Show contact details

Locations

NaRi Kim

Seoul, South Korea